share_log

iBio Inc | D: Filing D

iBio Inc | D: Filing D

iBio Inc | D:发行公告
美股SEC公告 ·  04/04 16:08
Moomoo AI 已提取核心信息
iBio Inc, a biotechnology company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice of an equity offering with the first sale dated 03/26/2024. The filing, signed by CEO Martin Brenner on 04/03/2024, reports a total offering and sold amount of $15,068,745 USD. The offering includes equity, options, warrants, and other rights to acquire securities, with no minimum investment from outside investors. The company has declined to disclose its revenue or aggregate net asset value. Eight investors have already invested in the offering, which is not being made in connection with a business combination transaction. Sales commissions are estimated at $794,124 USD. The proceeds from the offering are proposed to be used as working capital, which may indirectly include payments for salaries to employees, including executive officers. The offering is expected to last no more than one year, and iBio Inc has claimed an exemption under Rule 506(b) of the Securities Act.
iBio Inc, a biotechnology company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice of an equity offering with the first sale dated 03/26/2024. The filing, signed by CEO Martin Brenner on 04/03/2024, reports a total offering and sold amount of $15,068,745 USD. The offering includes equity, options, warrants, and other rights to acquire securities, with no minimum investment from outside investors. The company has declined to disclose its revenue or aggregate net asset value. Eight investors have already invested in the offering, which is not being made in connection with a business combination transaction. Sales commissions are estimated at $794,124 USD. The proceeds from the offering are proposed to be used as working capital, which may indirectly include payments for salaries to employees, including executive officers. The offering is expected to last no more than one year, and iBio Inc has claimed an exemption under Rule 506(b) of the Securities Act.
在特拉华州注册成立的生物技术公司iBio Inc已向美国证券交易委员会提交了D表格的证券豁免发行通知,表明了新的股票发行通知,首次出售日期为2024年3月26日。该文件由首席执行官马丁·布伦纳于2024年3月4日签署,报告总发行和销售金额为15,068,745美元。此次发行包括股权、期权、认股权证和其他收购证券的权利,外部投资者没有最低投资额。该公司拒绝透露其收入或总净资产价值。八位投资者已经投资了此次发行,该发行与企业合并交易无关。销售佣金估计为794,124美元。本次发行的收益拟用作营运资金,其中可能间接包括向包括执行官在内的员工支付的工资。此次发行预计将持续不超过一年,iBio Inc已根据《证券法》第506(b)条申请豁免。
在特拉华州注册成立的生物技术公司iBio Inc已向美国证券交易委员会提交了D表格的证券豁免发行通知,表明了新的股票发行通知,首次出售日期为2024年3月26日。该文件由首席执行官马丁·布伦纳于2024年3月4日签署,报告总发行和销售金额为15,068,745美元。此次发行包括股权、期权、认股权证和其他收购证券的权利,外部投资者没有最低投资额。该公司拒绝透露其收入或总净资产价值。八位投资者已经投资了此次发行,该发行与企业合并交易无关。销售佣金估计为794,124美元。本次发行的收益拟用作营运资金,其中可能间接包括向包括执行官在内的员工支付的工资。此次发行预计将持续不超过一年,iBio Inc已根据《证券法》第506(b)条申请豁免。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息